Stock Events

Stock Events

Galderma Group 

€208.00
48
-€6.00-2.8%Friday 08:04

Statistics

Day High
208
Day Low
208
52W High
214
52W Low
189
Volume
-
Avg. Volume
-
Mkt Cap
0
P/E Ratio
-
Dividend Yield
0.18%
Dividend
0.38

Upcoming

Dividends

0.18%Dividend Yield
Apr 2026
€0.38
Apr 2025
€0.07
Apr 2025
€0.09
10Y Growth
N/A
5Y Growth
N/A
3Y Growth
N/A
1Y Growth
438.17%

Earnings

Jul 23Expected
Q2 2026
1.98
2
2.03
2.06
Expected EPS
1.9773
Actual EPS
2.0563919999999998

Financials

11.78%Profit Margin
Profitable
2023
2024
2025
4.43BRevenue
521.7MNet Income

People Also Follow

This list is based on the watchlists of people on Stock Events who follow PY3.XETRA. It's not an investment recommendation.
Nestle SA
15
NESN.SW
Amazon
13
AMZN
Novartis
13
NOVN.SW
Zurich Insurance Group
12
ZURN.SW

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Johnson & Johnson
JNJ
Mkt Cap657.68B
Johnson & Johnson offers a wide range of skincare products through its consumer health division, directly competing with Galderma's offerings in the dermatological care market.
Novartis
NVS
Mkt Cap303.67B
Novartis, former parent company of Galderma, has a strong presence in the healthcare sector, including dermatology, competing in therapeutic areas similar to Galderma.
Pfizer
PFE
Mkt Cap173.95B
Pfizer competes in the pharmaceuticals sector including dermatology, offering products that overlap with Galderma’s therapeutic solutions.
Merck
MRK
Mkt Cap368.89B
Merck operates in the healthcare and pharmaceutical sectors with products that compete in dermatological conditions, a key area for Galderma.
Bristol-Myers Squibb
BMY
Mkt Cap127.71B
Bristol-Myers Squibb competes in various therapeutic areas including those that overlap with Galderma’s dermatology-focused portfolio.
Lilly(Eli) &
LLY
Mkt Cap1.26T
Eli Lilly competes in the pharmaceutical field with a focus on medical dermatology, offering treatments that can compete with Galderma’s products.
GSK
GSK
Mkt Cap99.19B
GlaxoSmithKline has a diversified healthcare portfolio that includes skin health products, competing with Galderma in the dermatology market.
Astrazeneca
AZN
Mkt Cap289.48B
AstraZeneca operates broadly in the pharmaceutical sector, including areas that compete with Galderma’s dermatological treatments.
Regeneron Pharmaceuticals
REGN
Mkt Cap95.99B
Regeneron Pharmaceuticals focuses on innovative treatments, including for skin diseases, which puts it in competition with Galderma’s dermatology products.

About

Galderma Group AG operates as a dermatology company worldwide. The company delivers a science-based portfolio of brands and services for the dermatology market, including injectable aesthetics, dermatological skincare, and therapeutic dermatology. Its portfolio of flagship brands includes Azzalure, ALLUZIENCE, Dysport, Restylane, Restylane Skinboosters, Sculptra, Cetaphil, ALASTIN, Soolantra, Epiduo, Epiduo Forte, Differin, AKLIEF, Oracea, Metvix, NEMLUVIO, Relfydess, Benzac, and Loceryl in therapeutic dermatology. The company was founded in 1981 and is headquartered in Zug, Switzerland.
Show More
CEO
Flemming Ørnskov
Employees
7676
Country
Switzerland
ISIN
CH1335392721
WKN
000A407X6

Listings

MX
MX
GALDN.MX
F
DE
PY3.F
MU
DE
PY3.MU
STU
DE
PY3.STU

0 Comments

Share your thoughts

FAQs

What is Galderma Group stock price today?▼
The current price of PY3.XETRA is €208.00 EUR — it has decreased by -2.8% in the past 24 hours. Watch Galderma Group stock price performance more closely on the chart.
What is Galderma Group stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on XETRA Stock Exchange exchange Galderma Group stocks are traded under the ticker PY3.XETRA.
When is the next Galderma Group earnings date?▼
Galderma Group is going to release the next earnings report on March 11, 2027.
What were Galderma Group earnings last quarter?▼
PY3.XETRA earnings for the last quarter are 2.06 EUR per share, whereas the estimation was 1.98 EUR resulting in a +4% surprise. The estimated earnings for the next quarter are N/A EUR per share.
What is Galderma Group revenue for the last year?▼
Galderma Group revenue for the last year amounts to 4.43B EUR.
What is Galderma Group net income for the last year?▼
PY3.XETRA net income for the last year is 521.7M EUR.
Does Galderma Group pay dividends?▼
Yes, PY3.XETRA dividends are paid annual. The last dividend per share was 0.38 . As of today, Dividend Yield (FWD)% is 0.18%.
How many employees does Galderma Group have?▼
As of November 7, 2026, the company has 7,676 employees.
In which sector is Galderma Group located?▼
Galderma Group operates in the Health & Wellness sector.
When did Galderma Group complete a stock split?▼
Galderma Group has not had any recent stock splits.
Where is Galderma Group headquartered?▼
Galderma Group is headquartered in Zug, Switzerland.